Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Given Consensus Rating of “Moderate Buy” by Brokerages

Posted by on Sep 18th, 2026

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $38.3333.

A number of analysts have issued reports on the stock. Guggenheim reiterated a “buy” rating and set a $43.00 price target on shares of Eloxx Pharmaceuticals in a research note on Monday, August 24th. Lifesci Capital assumed coverage on shares of Eloxx Pharmaceuticals in a report on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 price objective for the company. Lucid Cap Mkts raised shares of Eloxx Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 20th. Weiss Ratings started coverage on shares of Eloxx Pharmaceuticals in a report on Friday, August 14th. They set a “sell (d)” rating on the stock. Finally, Wall Street Zen raised shares of Eloxx Pharmaceuticals to a “hold” rating in a research report on Saturday, August 1st.

View Our Latest Report on Eloxx Pharmaceuticals

Eloxx Pharmaceuticals Trading Down 1.8%

Eloxx Pharmaceuticals stock traded down $0.31 during trading hours on Friday, reaching $17.24. The stock had a trading volume of 2,850 shares, compared to its average volume of 50,901. The company’s fifty day simple moving average is $15.80. Eloxx Pharmaceuticals has a 52 week low of $8.20 and a 52 week high of $23.40. The stock has a market cap of $69.65 million, a PE ratio of -11.19 and a beta of -1,862.26.

Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter.

About Eloxx Pharmaceuticals

(Get Free Report)

Eloxx Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nonsense mutations, which can prevent cells from producing functional proteins. The company’s research platform centered on ribosome modulation, an approach intended to encourage cells to read through certain premature stop signals in genetic instructions.

Its lead product candidate, ELX-02, was an investigational small-molecule therapy designed to promote the production of full-length proteins in diseases associated with nonsense mutations.

Read More

Analyst Recommendations for Eloxx Pharmaceuticals (NASDAQ:ELOX)

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.